The short answer
PubMed indexes roughly 135 Selank records. Mechanistic work, enkephalinase inhibition, BDNF expression, behavioural models,appears in international journals and is conducted in rodents. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry.
Key facts
- Selank PubMed records
- ~135
- Tuftsin PubMed records
- ~690
- Mechanistic journals
- Bull Exp Biol Med, Dokl Biol Sci
- Clinical journal
- Zh Nevrol Psikhiatr Im S S Korsakova
- Model organism
- Predominantly rat
- Earliest key mechanism paper
- 2001 (PMID 11550013)
- Western regulatory review
- None
The shape of the evidence
Selank's literature splits the same way Semax's does, which is unsurprising given the shared institute. Mechanistic and preclinical work appears in internationally indexed journals, the Bulletin of Experimental Biology and Medicine, Doklady Biological Sciences,and is accessible in English. Clinical work sits largely in Russian-language publications, indexed by translated title and often without accessible English full text.
The parent-analogue inversion
Tuftsin has roughly 690 indexed records against Selank's 135. For most designed analogues the derivative eventually outgrows the parent, because the parent was abandoned as impractical. Here the reverse holds, reflecting decades of immunological interest in tuftsin that predates and runs parallel to Selank rather than feeding into it. Anyone assessing Selank should know that most of the tuftsin literature is not about Selank at all.
Research material referenced
Selank 10mg, third-party HPLC tested
What can and cannot be assessed
The mechanistic claims can be evaluated directly. The enkephalinase papers describe what was measured and in what system. The clinical claims are harder to assess independently, not because the work does not exist but because language and access barriers sit between a reader and the methods. Neither dismissing that work nor accepting it uncritically is defensible.
Scale, in context
135 records is a small literature. BPC-157 and TB-500 have accumulated substantially more; a widely used approved medicine has thousands. Selank has been studied consistently but by a relatively narrow set of groups, and that concentration is itself relevant when weighing how independently the findings have been reproduced.
How to search it
PubMed indexes the field under 'Selank', and the development code TP-7 surfaces some older records the name misses. Filtering to English-language records isolates the internationally published mechanistic work; removing that filter shows how much of the clinical record sits outside it. Comparing the two counts is itself informative about the shape of the evidence.
Frequently asked questions
Are there Western clinical trials of Selank?
No substantial Western clinical programme exists, and no Western regulator has assessed it.
Why does tuftsin have more papers than Selank?
Tuftsin has been studied immunologically for decades independently of Selank. Most of that literature is not about Selank.
Which paper is the best starting point?
The 2001 Bulletin of Experimental Biology and Medicine paper on enkephalin-degrading enzymes, PMID 11550013, describes the most specific reported mechanism.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedZozulya AA et al., Selank and enkephalin-degrading enzymes. Bull Exp Biol Med 2001 (PMID 11550013)pubmed.ncbi.nlm.nih.gov
- PubMedZozulia AA et al., Peptide anxiolytic selank. 2008 (PMID 18454096)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Selank (Tuftsin Analogue) articles
- What Is Selank? Sequence, Origin and Enkephalin MechanismSelank is a synthetic heptapeptide built from tuftsin with a Pro-Gly-Pro extension. Structure, enkephalin mechanism, regulatory status and the evidence base.
- Selank's Enkephalinase MechanismSelank does not bind opioid receptors. Reported work shows it inhibits enkephalin-degrading enzymes, extending the half-life of the body's own enkephalins.
- Selank and GABAergic SignallingSelank has been reported to affect GABA-A receptor expression without binding the receptor directly - a different mechanism from benzodiazepines.
- Selank Storage, Stability and ReconstitutionSelank has no cysteine and no methionine, so the two usual degradation routes do not apply. What that changes about handling, and what it does not.